HSV-2 IgG Testing in Asymptomatic Patients: Not Recommended for Routine Screening
Routine HSV-2 IgG testing in asymptomatic patients is generally not recommended due to poor test specificity, high false-positive rates, and lack of evidence for improved clinical outcomes. 1
When Testing May Be Appropriate
The 2022 CDC guidelines explicitly state that screening for HSV-2 infection among asymptomatic adolescents and adults is not recommended for those with low pretest probability (few lifetime sexual partners, no known HSV-2 seropositive partners, no genital symptoms). 1 However, testing may be valuable in specific high-risk scenarios:
Consider Testing In:
- Patients with HSV-2 seropositive sexual partners - to guide counseling about transmission risk and suppressive therapy 1
- HIV-infected patients - due to increased risk and potential for more severe disease 2
- Patients at high risk for STDs who are motivated to reduce sexual risk behavior 2
- Patients with atypical genital symptoms where HSV cannot be ruled out by other means 1
Do NOT Test:
- Pregnant women - universal screening is not recommended 1
- General asymptomatic population with low pretest probability 1
Critical Test Performance Issues
The available HSV-2 IgG assays have serious limitations that make interpretation problematic in asymptomatic patients:
Specificity Problems
- HerpeSelect EIA specificity is only 57.4% compared to Western blot 1
- Index values of 1.1-2.9 have only 39.8% specificity 1
- Even index values ≥3.0 have only 78.6% specificity 1
- DiaSorin assay has 88.7% specificity for HSV-1 and 94.2% for HSV-2, with nearly one in three positive HSV-2 results being false positive at population prevalence of 12% 3
False Positives Are Common
- Patients with HSV-1 infection are more likely to have false-positive HSV-2 results with low index values 1
- In low-prevalence populations, positive predictive value drops dramatically 1
- False positives have been documented even at index values >3.5 1
If You Must Test: Confirmatory Strategy Required
Any positive HSV-2 IgG result with index value <3.0 MUST be confirmed with a second assay before disclosing results to the patient. 1
Recommended Confirmation Algorithm:
Initial test positive with index <3.0: Confirm with Biokit HSV-2 rapid assay or Western blot 1
Index ≥3.0: May be sufficient without confirmation, but be aware false positives still occur 1
Window period: Wait 12 weeks after potential exposure before testing, as antibodies may not be detectable earlier 1
Clinical Pitfalls to Avoid
Major Concerns:
- Psychosocial harm from false-positive diagnosis - labeling someone with lifelong STI based on unreliable test 4
- Testing without proper counseling - patients must understand test limitations before testing 1
- Inability to confirm positive results - if you cannot access confirmatory testing (Biokit or Western blot), reconsider testing asymptomatic patients 1
- Testing during window period - results may be falsely negative if tested <12 weeks post-exposure 1
What Recent Research Shows:
A 2024 study found no significant association between symptom history and HSV-2 antibody positivity 5, suggesting that even symptom-based screening may not effectively identify those who would benefit from testing. Among asymptomatic patients in that study, 31.2% tested positive, similar to those with symptoms.
The Bottom Line
The value of HSV-2 IgG testing in truly asymptomatic patients is limited by poor test performance and lack of evidence for improved outcomes. Testing should be reserved for specific high-risk scenarios where results will meaningfully change management (e.g., discordant couples considering suppressive therapy, HIV-infected patients). When testing is performed, providers must understand assay limitations, use confirmatory testing for low-positive results, and provide extensive pre- and post-test counseling. The current state of HSV-2 serological testing does not support routine screening of asymptomatic individuals. 1, 4